Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Sponsor
Zhongshan Hospital Xiamen University
Study ID
NCT04067986
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Colorectal Cancer Recurrent

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w One course will last 28 days. Oral administration at a dose of 250 mg/d
  • Apatinib — DRUG
    Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd

Study Details

The efficacy and safety of the use of Camrelizumab combined with Apatinib

Key Dates

Start date
Aug 20, 2019
Status verified
Sep 2020
Primary completion
Sep 23, 2020
Completion
Oct 31, 2021

Study Design

Enrollment
62 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Camrelizumab + Apatinib
    Camrelizumab + Apatinib

Primary Outcome Measure

Objective response rate [ Time Frame: one year ]

Central Contacts

Related Studies